<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860752</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02</org_study_id>
    <nct_id>NCT04860752</nct_id>
  </id_info>
  <brief_title>SAPIEN 3 Ultra EU PMS</brief_title>
  <official_title>SAPIEN 3 Ultra EU Post-Market Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate real-world outcomes for the SAPIEN 3 Ultra Transcatheter Heart Valve&#xD;
      System in transcatheter aortic valve implantation centres that are implementing minimalist&#xD;
      periprocedural practices and facilitating early discharge home.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, observational, single-arm, multicentre, post-market study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Length of index hospitalization</measure>
    <time_frame>Discharge, expected to be within 1-5 days post-procedure</time_frame>
    <description>Number of days in hospital after the procedure</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Aortic Valve Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation (TAVI)</intervention_name>
    <description>Subjects will undergo TAVI</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who will undergo TAVI with the Edwards SAPIEN 3 Ultra System as part of&#xD;
        standard-of-care treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Will undergo TAVI with the Edwards SAPIEN 3 Ultra System&#xD;
&#xD;
          2. Less than 80 years of age at time of the procedure&#xD;
&#xD;
          3. Low surgical risk&#xD;
&#xD;
          4. Meets clinical and procedural requirements for early discharge&#xD;
&#xD;
          5. The subject or subject's legal representative has been informed of the nature of the&#xD;
             study, agrees to its provisions and has provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical, social, or psychological conditions that preclude appropriate consent and&#xD;
             follow-up, including subjects under guardianship&#xD;
&#xD;
          2. Considered to be part of a vulnerable population&#xD;
&#xD;
          3. Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with&#xD;
             COVID-19 with sequelae that could confound endpoint assessments&#xD;
&#xD;
          4. Cannot tolerate an anticoagulation/antiplatelet regimen&#xD;
&#xD;
          5. Active bacterial endocarditis&#xD;
&#xD;
          6. Participating in a drug or device study that has not reached its primary endpoint&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Edwards THV Clinical Affairs</last_name>
    <phone>949-250-2500</phone>
    <email>THV_CT.gov@Edwards.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitatsspital Zurich</name>
      <address>
        <city>ZÃ¼rich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter aortic valve implantation (TAVI)</keyword>
  <keyword>SAPIEN 3 Ultra THV</keyword>
  <keyword>Edwards Lifesciences</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

